Podcasts about Prostate cancer screening

Howie and Harlan are joined by cardiologist Ali Rahimi, the founder of ALYKA Health, which uses a personalized mobile app to help patients manage their heart health between doctor's visits. Harlan discusses new developments in GLP-1 obesity drugs, including untested microdose treatments; Howie reviews a landmark study investigating whether broad prostate cancer screening saves lives. Show notes: GLP-1 Drugs "Microdosing aims to extend the lifespan of the GLP-1 compounding market" NIH: Regulatory Framework for Compounded Preparations Health & Veritas Episode 140: Lee Schwamm: Smarter Healthcare Systems With AI "FDA takes on GLP-1 compounding boom with warnings about misleading marketing" "Should You Microdose GLP-1 Drugs?" "How microdosing GLP-1 drugs became a longevity 'craze'" "Bidding war between Pfizer, Novo Nordisk for obesity startup Metsera escalates" "Trump Negotiating Deal With Ozempic Maker to Sell Some Weight-Loss Drugs for $149""Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment" "How Ozempic's Maker Lost Its Shine After Creating a Wonder Drug" Ali Rahimi ALYKA Health Harlan Krumholz and Ali Rahimi, "Financial Barriers to Health Care and Outcomes After Acute Myocardial Infarction" "Why High Blood Pressure Matters to Your Health" Building a Better Delivery System: A New Engineering/Health Care Partnership NIH: The 21st Century Cures Act New Evidence on Prostate Cancer Screening and Breast Cancer Treatment National Cancer Institute: Cancer Stat Facts: Prostate Cancer" U.S. Preventive Services Task Force: Prostate Cancer: Screening" "The pros and cons of PSA tests for prostate cancer for midlife and older men" "Share on European Study of Prostate Cancer Screening — 23-Year Follow-up" "Early Detection of Prostate Cancer — Time to Fish or Cut Bait" "Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer" "Omission of Chest-Wall Irradiation after Mastectomy for Breast Cancer" In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.  

Howie and Harlan are joined by cardiologist Ali Rahimi, the founder of ALYKA Health, which uses a personalized mobile app to help patients manage their heart health between doctor's visits. Harlan discusses new developments in GLP-1 obesity drugs, including untested microdose treatments; Howie reviews a landmark study investigating whether broad prostate cancer screening saves lives. Show notes: GLP-1 Drugs "Microdosing aims to extend the lifespan of the GLP-1 compounding market" NIH: Regulatory Framework for Compounded Preparations Health & Veritas Episode 140: Lee Schwamm: Smarter Healthcare Systems With AI "FDA takes on GLP-1 compounding boom with warnings about misleading marketing" "Should You Microdose GLP-1 Drugs?" "How microdosing GLP-1 drugs became a longevity 'craze'" "Bidding war between Pfizer, Novo Nordisk for obesity startup Metsera escalates" "Trump Negotiating Deal With Ozempic Maker to Sell Some Weight-Loss Drugs for $149""Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment" "How Ozempic's Maker Lost Its Shine After Creating a Wonder Drug" Ali Rahimi ALYKA Health Harlan Krumholz and Ali Rahimi, "Financial Barriers to Health Care and Outcomes After Acute Myocardial Infarction" "Why High Blood Pressure Matters to Your Health" Building a Better Delivery System: A New Engineering/Health Care Partnership NIH: The 21st Century Cures Act New Evidence on Prostate Cancer Screening and Breast Cancer Treatment National Cancer Institute: Cancer Stat Facts: Prostate Cancer" U.S. Preventive Services Task Force: Prostate Cancer: Screening" "The pros and cons of PSA tests for prostate cancer for midlife and older men" "Share on European Study of Prostate Cancer Screening — 23-Year Follow-up" "Early Detection of Prostate Cancer — Time to Fish or Cut Bait" "Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer" "Omission of Chest-Wall Irradiation after Mastectomy for Breast Cancer" In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.  

"[When] a lot of men think about prostate exams, they immediately think of the glove going on the hand of the physician, and they immediately clench. But really try to talk with them and discuss with them what some of the benefits are of understanding early detection. Even just having those conversations with their providers so that they understand what the risk and benefits are of having screening. And then educate patients on what a prostate-specific antigen (PSA) and digital rectal exam (DRE) actually are—how it happens, what it shows, and what the necessary benefits of those are," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer screening, early detection, and disparities. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 31, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to prostate screening, early detection, and disparities. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ Episode 149: Health Disparities and Barriers in Metastatic Castration-Sensitive Prostate Cancer ONS Voice articles: Gender-Affirming Hormones May Lower PSA and Delay Prostate Cancer Diagnosis in Transgender Women Healthy Lifestyles Reduce Prostate Cancer Mortality in Patients With Genetic Risk Hispanic Patients Are at Higher Risk for Aggressive Prostate Cancer but Less Likely to Get Treatment Leveling State-Level Tax Policies May Increase Equality in Cancer Screening and Mortality Rates Most Cancer Screening Guidelines Don't Disclose Potential Harms ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing article: Barriers and Solutions to Cancer Screening in Gender Minority Populations Oncology Nursing Forum articles: Disparities in Cancer Screening in Sexual and Gender Minority Populations: A Secondary Analysis of Behavioral Risk Factor Surveillance System Data Symptom Experiences Among Individuals With Prostate Cancer and Their Partners: Influence of Sociodemographic and Cancer Characteristics Other ONS resources: Genomics and Precision Oncology Learning Library ONS Biomarker Database (refine by prostate cancer) American Cancer Society prostate cancer early detection, diagnosis, and staging page National Institutes of Health prostate cancer screening page U.S. Preventive Services Task Force prostate cancer screening recommendation statement To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "The recommendations are men [aged] 45 who are at high risk, including African American men and men who have a first-degree relative who has been diagnosed with prostate cancer younger than 65 should go through screening. And men aged 40 at an even higher risk, these are the men that have that one first-degree relative who has had prostate cancer before 65. Screening includes the PSA blood test and a digital exam. Those are the screening recommendations, although they are a little bit controversial." TS 3:42 "You still see PSAs and DREs as the first line because they're easier for primary care providers to perform. ... Those are typically covered by insurance, so they still play that role in screening. But with the advent of MRIs and biomarkers, these have really helped refine that screening process and determine treatment options for our patients. Again, those patients who may be at a bit of a higher risk could go for an MRI or have biomarkers completed. Or if they're on that verge with their Gleason score, instead of doing a biopsy, they may send the patient for an MRI or do biomarkers for that patient. ... These updated technologies put [patients] a little bit more at ease that someone's watching what's going on, and they don't have to have anything invasive done to see where they're at with their staging." TS 4:35 "Disparities in screening access exist based on race, socioeconomic status, gender identity, education, and geography. It's really hard in rural areas to get primary care providers or urologists who can actually see these patients, [and] sometimes in urban areas. So socioeconomic status can affect that, but also where a person lives. African American men with lower incomes and people in rural areas face the greatest barriers to receiving screening. It's also important to encourage anyone with a prostate to be screened and offer gender-neutral settings for patients to feel comfortable." TS 7:50 "I think a lot of men feel like if they have no symptoms, they don't have prostate cancer ... so a lot of patients may put off screening because they feel fine, [they] haven't had any urinary symptoms, it doesn't run in their family. ...With prostate cancer, there usually are not symptoms that a patient's having—they may have some urinary issues or some pain—but it's not very frequent that they have that. So, just making sure our patients understand that even though they're not feeling something, it doesn't mean there's not something else going on there." TS 12:53 "Prostate cancer found at an early age can be very curable, so it's really important for men to have those conversations with their providers about the risk and benefits of screening. And anyone that we can help along the way to be able to have those conversations, I think is a great thing for oncology nurses to do." TS 15:44

Host: Darryl S. Chutka, M.D. Guest: Daniel M. Frendl, M.D., Ph.D. If your practice includes middle age and older men, you've very likely diagnosed prostate cancer. It's the most diagnosed non-skin cancer in men in the U.S. Its incidence rises with age, with a median age of around 66 years. When found early, prostate cancer is very treatable, and in most cases, curable. Prostate specific antigen, or PSA is very effective in detecting early prostate cancer, but its use has been controversial due to the risk of overdiagnosis and overtreatment. What are the current recommendations for prostate cancer screening with PSA? What's the role of the digital rectal exam? How should we be using the PSA and what other tests are available for prostate cancer screening? The topic for this podcast is “Prostate Cancer Screening” and I'll be asking these questions to my guest, Daniel M. Frendl, M.D., Ph.D., a urologist at the Arizona campus of the Mayo Clinic. Tune in this Thursday for our next episode on "Prostate Cancer" releasing October 30, 2025. Connect with us and learn more here: https://ce.mayo.edu/online-education/content/mayo-clinic-podcasts 

This week Bobbi Conner talks with MUSC's Dr. Eric Wallen about prostate cancer screening.

In this Healthed lecture, the experts will answer questions about changes to the prostate cancer screening guidelines including the updated risk: benefit profile for PSA testing, who should have this test and how PSA test results should now be interpreted and managed. In addition, this case-based discussion will cover the practical application of the new draft guidelines on prostate cancer screening that are likely to be endorsed and become standard of care in the near future.See omnystudio.com/listener for privacy information.

What is the role of PSA for early detection, and how does hormone therapy affect cancer patients? These are questions we dig into in this episode. https://bit.ly/4lC0ZUdIn This Episode:01:32 - Road Trip-South Carolina & Shout Halellujah Potato Salad02:38 - Fighting For Your Life Is Boring - Andrew Reynolds04:44 - Prostate Cancer - Risks and Treatment09:46 - Why Was Biden's Prostate Cancer Detected So Late?14:52 - Signs and Symptoms of Prostate Cancer16:08 - Gleason Scoring for Prostate Cancer Grade19:18 - Hormone Therapy - Androgen Deprivation33:27 - Prostate Cancer and Partners36:21 - OutroAbout 1 in 8 men will be diagnosed with prostate cancer during their lifetime. Prostate cancer is the second-leading cause of cancer death in American men, behind lung cancer. Learn signs and symptoms, the role of PSA (prostate-specific antigen) for early detection and monitoring, how androgen-blocking therapy works, and how it affects patients and their partners.Support the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

Last month, former President Joe Biden announced that he had been diagnosed with an aggressive form of prostate cancer. The news sparked a larger conversation about what exactly the best practices are to screen for prostate cancer. Turns out, it's more complicated than it might seem. Host Ira Flatow is joined by oncologist Matthew Cooperberg and statistician Andrew Vickers, who studies prostate cancer screening, to help unpack those complexities.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Prostate cancer screening isn't just clinical—it's personal. Especially when headlines make it political.In this episode Tracy breaks down the buzz around President Joe Biden's recent prostate cancer diagnosis—and uses the moment to teach, clarify, and contextualize what it really means to screen for prostate cancer in 2025.As a former Urology PA, Tracy brings her clinical experience and clear communication to an often-misunderstood topic. She walks through:What the prostate does and how PSA testing worksWhat elevates PSA levels (that isn't cancer)Why BPH complicates the pictureWhat Gleason scores tell us about cancer aggressivenessCurrent USPSTF and AUA guidelines for prostate cancer screeningHow shared decision-making, not headlines, should guide patient careThis episode is a reminder to return to nuance and individualize care—especially when the world is watching.

What do Diddy's “black hotel bag” with many secrets, President Joe Biden's prostate cancer diagnosis, LaVar Ball's diabetes amputations, and a surgeon accidentally removing a woman's healthy kidney have in common? They're all making headlines - and we're breaking them down, no sugarcoating, no medical mumbo jumbo! We're dissecting these medical headlines with a dose of evidence-based facts and the kind of practical advice you'll actually remember when it counts.By the way, have you heard of “Ozempic teeth”? Don't worry, we'll break that down too, plus a whole lot more. And just because it's Memorial Day, I'm giving you my top 5 tips for a healthy summer with a twist! Let's get into it together, laugh a little, and leave a lot smarter.This podcast is intended to be informational only.  It is not a medical consultation, nor is it personalized medical advice.  For medical advice, please consult your physician.#HealthHappyLifePodcast #DrFrita #MedicalMondays #MedicineInTheNewsHere are a few helpful resources to help on your journey to wellness:▶️ Subscribe so you will never miss a YouTube video.

AP correspondent Ben Thomas reports former President Biden's office is providing more information about his health screenings.

Hour 3 for 5/19/25 Drew discussed prostate cancer screening with Dr. Umang Gautam (1:00). Topics: frozen treatment (10:58), early testing (12:43), caller: cancer survivor (13:39), caller: my husband's health story (19:17), health foods (21:15), and caller: I had cancer (24:57). Then, Fr. Burke Masters discussed Pete Rose's Hall of Fame ban lifted (31:54). Topics: ethics in baseball (35:46), caller: I think he should be in the Hall of Fame (39:00), and caller: I think there is a lot of hypocrisy in sports (42:34), and morality in sports (45:46).

A polygenic risk score significantly improved prostate cancer detection beyond PSA testing, identifying more treatable and aggressive cancers in high-risk men. New WHO guidelines aim to reduce global meningitis deaths by standardizing early diagnosis, treatment, and care across settings. GLP-1 receptor agonists and SGLT2 inhibitors were linked to reduced Alzheimer's risk, with GLP-1s showing the most consistent neuroprotective effects in recent studies. Lastly, breast cancer mortality was 47% higher among Black women living in disadvantaged neighborhoods, underscoring the impact of social determinants on survival.

Masood Moghul, MBBS, a urologist and Research Fellow at the Royal Marsden Hospital and Institute of Cancer Research in London shared findings from a study investigating a mobile, targeted, case-finding approach to prostate cancer detection with 3,379 patients. Moghul told the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco how the study addressed health inequalities and barriers to accessing health care that affect prostate cancer in high-risk underserved groups.

Masood Moghul, MBBS, a urologist and research fellow at the Royal Marsden Hospital and Institute of Cancer Research in London, UK, discussed his group’s findings from the Man Van study investigating a mobile, targeted, case-finding approach to prostate cancer detection with 3,379 patients conducted in Greater London. Moghul told the 2025 ASCO Genitourinary Cancers Symposium in San Francisco how the study had addressed health inequalities and barriers to accessing health care that affect prostate cancer in high-risk underserved groups.

In this edition of The Naked Scientists: A new screening test for prostate cancer that can, the inventors claim, accurately catch 96% of cases, and early. Also, why you might want to eschew artificial sweeteners: a new study suggests they can accelerate arterial disease. And, scientists show that turtles can sense magnetic fields to find their way around... Like this podcast? Please help us by supporting the Naked Scientists

LOUNGE LIZARDS PRESENTED BY FABRICA 5 - Visit Fabrica005.com and use code LIZARDPOD at checkout for 10% off THE ENTIRE STORE! Free worldwide shipping from Miami on all orders over $125. See website for more information and terms.Recorded at Ten86 Cigars in Hawthorne, New Jersey, the lizards pair Arturo Fuente Don Carlos The Man with Redbreast Iberian Series Lustau Edition. The guys read a listener email about prostate cancer and detecting it early, they enjoy some Whiskey ASMR, they discuss Car Smoking Accessories and Chef Ricky gives an update on his new tower.Plus: Preferred Hygrometers and More Generational Smoking BansJoin the Lounge Lizards for a weekly discussion on all things cigars (both Cuban and non-Cuban), whiskey, food, travel, life and work. This is your formal invitation to join us in a relaxing discussion amongst friends and become a card-carrying Lounge Lizard yourself. This is not your typical cigar podcast. We're a group of friends who love sharing cigars, whiskey and a good laugh.website/merch/rating archive: loungelizardspod.comemail: hello@loungelizardspod.com to join the conversation and be featured on an upcoming episode!instagram: @loungelizardspodGizmo HQ: LizardGizmo.com

Prostate cancer screening is an essential aspect of men's health, and current advancements in testing are making early detection more precise than ever before. While the PSA (Prostate-Specific Antigen) test has long been the standard, it has limitations and may lead to unnecessary biopsies. The new EpiSwitch PSE test helps differentiate between high and low prostate cancer risks. With an impressive 94% accuracy rate, the EpiSwitch PSE test empowers patients and physicians to make informed decisions. In this episode, Dr. Garrett Pohlman explores the latest innovations in prostate cancer screening, focusing on the EpiSwitch PSE blood test.  Stay tuned to discover the benefits of the new EpiSwitch PSE test and learn how precision medicine is reshaping prostate cancer management for men. Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation. Show Highlights: What are the limitations of the PSA test? How the EpiSwitch PSE test can predict the risk of prostate cancer with 94% accuracy How prostate cancer biomarkers help to identify the likelihood of prostate cancer  How the EpiSwitch PSE test can provide a more accurate assessment of prostate cancer risk How the EpiSwitch PSE test can help men avoid unnecessary biopsies The clinical applications of the EpiSwitch PSE test and how it can be used alongside a standard PSA test to improve accuracy How the EpiSwitch PSE test requires just two milliliters of blood  How even patients who have undergone recent BPH procedures or are on 5-alpha reductase inhibitors can use the EpiSwitch PSE test Why the EpiSwitch PSE test is more accurate than PSA testing Why men need to be aware of their PSA numbers and consider additional testing if they have an elevated PSA Pertinent disclosures for this episode:  Dr. Garrett Pohlman is a Consultant for Oxford BioDynamics Links:  Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd  Get your free What To Expect Guide (or find the link on our podcast website)   Join our Facebook group  Follow Dr. Pohlman on Twitter and Instagram  Go to the Prostate Health Academy to sign up.  You can access Dr. Pohlman's free mini webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here.  

Jonathan Shoag, MD, discusses his innovative prostate cancer research aiming to better understand the impact of PSA screening and his groundbreaking work on the genetics of aging. About Jonathan Shoag, MD Learn more about the University Hospitals Research & Education Institute Follow Us on Social:      

Guidelines for breast cancer screening have been gradually shifting, and urologists say prostate cancer screening guidelines also need to be updated. Our house doctor, Mike Simon speaks with host Steven Webb about the importance of early screening for prostate cancer.

Prostate cancer is the second most common cancer in men, behind only skin cancer. In recent years, advances in screening, surgery and radiation treatment have improved outcomes and led to an increase in what is known as active surveillance after the initial diagnosis of prostate cancer. “The goal of active surveillance is to maximize the quality of life for patients while at the same time preserving the quantity of life,” said Akshay Sood, MD, a James urologic oncologist who specializes in treating prostate and bladder cancer. Dr. Sood explained the importance of screening, the prostate-specific antigen (PSA) test and what it means, the Gleason score and how these numbers help oncologists determine when to treat patients. He also discussed what's involved in prostate-cancer surgery and radiation treatments, and advances in both of these areas. Dr. Sood is also one of the leaders of the James Multidisciplinary Prostate Cancer Clinic and he described the benefits to patients of this all-in-one clinic that includes a large team of prostate cancer experts. “Unfortunately, there are no symptoms, which is why screening is so important,” Dr. Sood said of prostate cancer. PSA screening should begin at the age of 45 for most men. African American men (who have a higher rate of prostate cancer) and those with a family history of prostate and other types of cancers should begin their yearly PSA screenings at 40. “A PSA level below 4 is considered normal, while a score above 4 is abnormal,” Dr. Sood said. A high score will often lead to a biopsy to determine of the patient has cancer and, if they do, where it ranks on the Gleason scale and the genetic mutation causing the cancer.

Richard Hoffman, MD, MPH, Emeritus Professor of Internal Medicine, University of Iowa Carver College of Medicine CME Credit Available for All Providence Providers In order to claim CME credit, please click on the following link: https://forms.office.com/r/Pd7LVJFyfh ⁠ ⁠⁠⁠(or copy & paste into your browser) Accreditation Statement: Providence Oregon Region designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1  creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Providence Oregon Region is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Planning Committee & Faculty Disclosure: The planning committee and faculty have indicated no relevant financial relationships with an ACCME-defined ineligible company. Their planning contributions were evidence-based and unbiased. All financial relationships (if any) have been mitigated. Original Date: November 19, 2024 End Date: November 19, 2025

Richard Hoffman, MD, MPH, Emeritus Professor of Internal Medicine, University of Iowa Carver College of Medicine CME Credit Available for All Providence Providers In order to claim CME credit, please click on the following link: https://forms.office.com/r/Pd7LVJFyfh ⁠ ⁠⁠⁠(or copy & paste into your browser) Accreditation Statement: Providence Oregon Region designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1  creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Providence Oregon Region is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Planning Committee & Faculty Disclosure: The planning committee and faculty have indicated no relevant financial relationships with an ACCME-defined ineligible company. Their planning contributions were evidence-based and unbiased. All financial relationships (if any) have been mitigated. Original Date: November 19, 2024 End Date: November 19, 2025

In this episode, we have the pleasure to interview Dr Romain Diamand, from Hôpital Bordet in Bruxelles (Belgium). Together, we talk about what will be the prostate cancer screening of the future: Which techniques? Which technologies? Which trends?Hosted by Ausha. See ausha.co/privacy-policy for more information.

Broadcast from KSQD, Santa Cruz on 10-10-2024: Dr. Dawn announces Medicare's new list of over 200 drugs available for $2 per 30-day supply, covering a wide range of medications. She discusses a new urine test called ExoDx for prostate cancer screening, which can help avoid unnecessary biopsies in the "gray zone" of elevated PSA levels. The doctor addresses a listener's question about Klebsiella pneumoniae found in a nasal swab, explaining colonization versus infection and the risks of unnecessary antibiotic use. Dr. Dawn explores the reliability of QuantiFERON TB tests, suggesting potential false positives and the importance of retesting with different antigen tubes. She discusses orthostatic hypotension in older adults, offering practical tips like squeezing a firm ball before standing up and proper standing techniques to prevent falls. The doctor explains the importance of vitamin A for vegans, highlighting potential BCMO1 genetic variations that may affect beta-carotene conversion and recommending blood tests. Dr. Dawn addresses a question about elevated bilirubin levels post-gallbladder removal, discussing possible causes and diagnostic procedures like MRI and ERCP.

Broadcast from KSQD, Santa Cruz on 10-10-2024: Dr. Dawn announces Medicare's new list of over 200 drugs available for $2 per 30-day supply, covering a wide range of medications. She discusses a new urine test called ExoDx for prostate cancer screening, which can help avoid unnecessary biopsies in the "gray zone" of elevated PSA levels. The doctor addresses a listener's question about Klebsiella pneumoniae found in a nasal swab, explaining colonization versus infection and the risks of unnecessary antibiotic use. Dr. Dawn explores the reliability of QuantiFERON TB tests, suggesting potential false positives and the importance of retesting with different antigen tubes. She discusses orthostatic hypotension in older adults, offering practical tips like squeezing a firm ball before standing up and proper standing techniques to prevent falls. The doctor explains the importance of vitamin A for vegans, highlighting potential BCMO1 genetic variations that may affect beta-carotene conversion and recommending blood tests. Dr. Dawn addresses a question about elevated bilirubin levels post-gallbladder removal, discussing possible causes and diagnostic procedures like MRI and ERCP.

Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker. In this episode, we have three exciting new papers. Firstly, in the BMJ a network meta-analysis on acute migraine treatments - can the new GEPANTs drugs beat existing therapies? Secondly, a paper in NEJM does screening for prostate cancer using MRI actually help? Finally in the BJGP can first contact physio be better than a GP appointment? Listen on! ReferencesBMJ Acute migraine therapiesNEJM Prostate cancer screening with MRIBJGP First contact physio in GPwww.nbmedical.com/podcast

Requested by KP listeners! An update on a patient from the previous prostate cancer episode and a deep dive into the history of prostate cancer screening. References: Kazuto, I. et al. Screening for prostate cancer: History, evidence, controversies and future perspectives toward individualized screening. International journal of urology. 2019; 26(10). doi:10.1111/iju.14039 Albertsen PC. The Evolving Paradigm of Prostate Cancer Screening. JAMA Netw Open. 2019;2(8):e198392. doi:10.1001/jamanetworkopen.2019.8392 USPSTF Final Recommendation Statement: Prostate Cancer Screening, 2018. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline part I: prostate cancer screening. J Urol. 2023;210(1):45-53.

House Doctor Peter Lin brought us his reflections on a new medical test. It can help identity genetic markers that are linked the most aggressive cases of prostate cancer.

Hello and welcome to HBR News where we talk about the news of the week! This week we discuss what might be some good news such as advancements in prostate cancer screenings, Prince William opens a clinic for men, and more!

Editor's Summary by Anne Rentoumis Cappola, MD, ScM, Associate Editor of JAMA, the Journal of the American Medical Association, for the May 7, 2024, issue.

A major study will vet methods of screening men for prostate cancer for effectiveness in a bid to save thousands of lives each year. How ‘wall of death' space workout keeps astronauts fit - with Alberto Minetti, professor of physiology at the University of Milan. Infected blood scandal compensation schedule agreed.Also in this episode:Perimenopausal women ‘more likely to suffer depression'Half of London children not getting exercise hour.Climate change UK spider influx warningWorld's largest blue hole found Hosted on Acast. See acast.com/privacy for more information.

Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker. To DRE or not to DRE? This is the question and the main event in this episode. We have a fantastic interview with Amy Rylance, Head of Improving Care at Prostate Cancer UK, and Sam Merriel, GP and academic clinical lecturer, discussing their recent Clinical Practice paper in the BJGP: Is the digital rectal exam any good as a prostate cancer screening test? In other research, we have two papers with a common theme. Firstly, a paper in the BMJ looking at long-term outcomes after diagnosis with atrial fibrillation, and secondly, a paper in the BJGP examining the role of BNP testing as a marker for future cardiovascular disease in patients with a new diagnosis of hypertension. Both show that while these conditions make us think of stroke and MI, we also should be thinking about heart failure. ResourcesBJGP Clinical Practice paper on DRE for prostate cancer screeningProstate Cancer UK Patient Risk CheckerEuropean Urology Oncology Journal Performance of DRE in PCa ScreeningNEJM 2004 Prevalence of PCa in men with a PSA

This week, in recognition of Colorectal Cancer Awareness Month, we engage in a conversation with Dr. Robert Zaiden, MD, FACP, focusing on ctDNA testing in GI cancers and his team's contributions.Dr. Zaiden, a seasoned medical oncologist in Jacksonville, FL, specializing in GI/GU tumors, stands as one of the founding members of Baptist MD Anderson. His active participation and leadership in various committees, including the role of Physician-in-Chief and Head of Cancer Medicine ad interim, underscore his commitment to optimizing patient care. Serving as the current director of the GI Tumor board, he has been instrumental in the rapid growth of Baptist MD Anderson.With a wealth of experience, Dr. Zaiden has been a Principal Investigator or Sub-Investigator in over 20 clinical trials. Recognized with prestigious awards such as Physician of the Year and Teaching and Excellence awards, he is also the Medical Director of Infusion Centers at BMDA.Before joining Baptist Medical Center in 2015, Dr. Zaiden contributed to the Hematology/Oncology faculty at the University of Florida in Jacksonville. During his tenure at UF, he received the Outstanding Resident Teacher award and was consistently voted Exemplary Faculty Teacher for five consecutive years. Beyond his professional accomplishments, Dr. Zaiden actively promoted Colorectal and Prostate Cancer Screening awareness to underserved communities, delivering cancer awareness talks at the YMCA. He proudly received the WeCare Patient's Choice award in 2023.This episode is sponsored by Walgreens. Our expert oncology-specialized pharmacy team is here for you. Our patients are at the heart of what we do and our pharmacists offer expert and compassionate support throughout each patient's unique cancer journey. Let's work together to care for the whole patient. Click here to find a Walgreens oncology-specialized pharmacist near you.

The questions answered in this podcast are listed below.They were compiled by GPs and health professionals around Australia.1. My patient was told by a doctor that duodart may cause cancer - thoughts? 2. What's the utility of PSA in the monitoring for relapse of metastatic prostate cancer where treatment had been deemed successful at suppressing growth, but prostatectomy had not been performed? I know this is not a screening question as such, but it sounds like to me the oncology team is using PSA as a "screening" test for relapse in this patient in this context since he is not on active treatment?3. How important is “above the mean” but < 3 PSA level mean?4. What about rate of rise of PSA? Link with prostate cancer?5. Are we routinely check PSA for men >50 year old every 2 years in general practice?6. Will you do random sampling via transperineal biopsy for patients who are MRI contraindicated? Or is there another imaging modality e.g. PET scan7. Healthy man of 70 year old, should or should not he have PSA testing?8. Is a PSA level of 3 used as cut off across age groups? 9. People with family history - How do you screen? I learnt a few years ago  0.35 rise per year is acceptable more than that need to be investigated. What are the guidelines with or without family history to screen for prostate cancer? 10. Is the upper age limit for PSA likely to change given that men are living longer?11. How many patients on active surveillance actually develop metastatic prostate cancer and missed the chance of curative treatment?12. If PSA is >6, will the patient get Medicare rebate for repeating the PSA 1-3 months later? I was under impression PSA Medicare rebate is only available once every 12 months13. What management or follow up is recommended for men with PSA within the normal range but above the median for their age group?14. Why was the transrectal biopsy ever done instead of trans perineal from the get-go? Is it technically easier?15. What MRI is recommended for detecting prostate cancer? 16. How far are we to use AI for reporting MRI prostate?17. Why we don't do MRI screening rather PSA18. For patient with PSA > 3.0, if repeat test after 1-3 months showed PSA < 3.0, do we repeat screening again in 2 years, or earlier?19. What are some comments you might have about risk mitigation in the diagnosis of prostate cancer? Host: Dr David Lim | Total Time: 43 mins Guests: Prof Jeremy Grummet, Urologist Register for our fortnightly FREE WEBCASTSEvery second Tuesday | 7:00pm-9:00pm AEDT Click here to register for the next oneSee omnystudio.com/listener for privacy information.

How did the COVID-19 pandemic affect clinical outcomes in patients with diabetes? Find out about this and more in today's PV Roundup podcast.

Do you know that prostate cancer is the second most prevalent cancer in American men, following skin cancer? A new diagnosis of prostate cancer occurs every two minutes. We are delighted to partner with Oxford Biodynamics for today's episode with Dr. Robert Heaton, who joins us to discuss a ground-breaking new prostate cancer screening test that predicts the risk of prostate cancer with 94% accuracy, using a simple blood test. Dr. Heaton is a board-certified pathologist. He completed his medical training at Georgetown University and then spent the next twenty years in the US Navy. After finishing his residency training in pathology, Dr. Heaton became the Director of Laboratory and Clinical Support Services for the National Naval Medical Center before joining various hospital pathology labs and life sciences companies. He is currently the Laboratory Medical Director for Oxford Biodynamics at their CLIA-certified clinical lab in Maryland, where he oversees the clinical operations of their liquid biopsy blood tests. In today's episode, we dive into the details of the innovative EpiSwitch Prostate Screening test, known as the PSE, designed to confirm the presence of prostate cancer, whether symptoms are present or not. This technological advancement is a game-changer! It empowers urologists by providing a precise tool to assess whether a patient should undergo a biopsy or opt for continued monitoring. Stay tuned to learn how this simple yet powerful tool streamlines the screening process for men struggling with prostate cancer. Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation.   Show Highlights: At what age should men start getting checked for prostate cancer?  What the screening for prostate cancer typically entails The importance of establishing a baseline to monitor how PSA changes over time Dr. Heaton dives into the details of the EpiSwitch PSA test How men can access the EpiSwitch PSA test Dr. Heaton discusses the accuracy of the EpiSwitch PSA test What is the expected turnaround time for the EpiSwitch PSC test results? Dr. Heaton explains the role of the Epi Switch PSA test in different scenarios The revolutionary EpiSwitch Prostate Screening test has remarkable accuracy in predicting prostate cancer risk through a simple blood test. It holds immense promise for men battling prostate cancer by providing urologists with a precise diagnostic tool and offering a streamlined approach for patients facing the complexities of prostate cancer. Links: Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd Get your free What To Expect Guide (or find the link on our podcast website)   Join our Facebook group  Follow Dr. Pohlman on Twitter and Instagram  Go to the Prostate Health Academy to sign up.  You can access Dr. Pohlman's free mini webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here. Oxford BioDynamics: Website LinkedIn  Facebook Twitter: @oxbiodynamics and #OBD Instagram: @oxbiodynamics YouTube: @oxfordbiodynamics PSE: Website LinkedIn Facebook Twitter: (@94percent_com) Instagram: (@get_the_pse)

In this Healthed lecture, Associate Professor Jeremy Grummet will explain how the recent major changes in routine practice including MRI, transperineal biopsy and active surveillance have mitigated the risks of overtreatment of unharmful types of prostate cancer enormously, and provide the very latest evidence-based thinking on PSA testing to inform your daily practice.See omnystudio.com/listener for privacy information.

Thank you for joining us, today we will be reviewing prostate cancer screening and potential benefits as well as any associated controversies. The main focus of our discussion today revolves around PSA, or prostate-specific antigen. Although  treating prostate cancer at an early stage to avoid long-term consequences, including potential metastatic disease, is important, we must acknowledge that our screening tools are imperfect. We don't want to diminish the importance of treating an aggressive prostate cancer, but simply want to highlight that screening should not be done without a thorough explanation between you and your patient. Author: Nickolas Coombs, DO Host/Editor: Rob Harmon, DO

Common themes for discussion on this podcast include overdiagnosis, approaches to the testing, the ins and outs of explanations, as well as other issues facing GPs who are overburdened, and have limited time and resources to treat patients. A topic which draws all of these themes together is prostate cancer screening. The BMJ recently published a feature which asked whether the UK is ready to roll out a nationwide prostate cancer screening programme, and the linked analysis paper, authored by Dr Andrew Vickers and colleagues, argued that the current model of screening, which determines testing by shared decision making, is the worst approach for detecting prostate cancer. We spoke to Andrew Vickers to discuss this further, and our second interview was with Dr Sam Merriel, regarding the emerging evidence that suggests that taking an MRI scan prior to biopsy could decrease harms associated with overdiagnosis and overtreatment of prostate cancer.   Our guests: Andrew Vickers is an attending research methodologist in the Department of Epidemiology and Biostatistics at Memorial Sloan Kettering Cancer Center, New York. Sam Merriel is a GP, and a researcher on cancer diagnostic testing at the University of Exeter.   Further reading: ‘Is the UK really ready to roll out prostate cancer screening?' BMJ 2023;381:p1062  ‘Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit' BMJ 2023;381:e071082   

Vidcast: https://www.instagram.com/p/CtvngjiMJsY/ Combining genetic information with conventional Prostate Specific Antigen, PSA, test results sharpens the precision and the predictive value of conventional PSA tests.  Multi-disciplinary researchers at UC-San Francisco and the Stanford Cancer Institute studied 95,768 men and discovered 128 specific genetic associations with prostate cancer.  Using this data, they developed a PSA polygenic score that, when combined with conventional PSA levels was 3.4 times more predictive of aggressive prostate cancer than raw PSA values.  Such hybrid PSA testing could avoid as many as 31% of negative prostate biopsies for screening purposes and as many 12% of such biopsies for follow up after prostatic cancer therapy. https://www.nature.com/articles/s41591-023-02277-9 #psa #prostatecancer #genetics #precisiononcology

This webcast will discuss Prostate Cancer Screening.

In the first hour of "Connections with Evan Dawson" on Monday, April 17, 2023, guest host Eric Logan discusses the latest in prostate cancer screening, research and treatment.

A lot of people care about their health, but the fear of the unknown can sometimes stop them from being screened for cancer. One way to help is by holding free cancer screenings. Volunteers help put people at ease through education. Free cancer screenings also make the process more accessible to people who otherwise can't afford medical care.  Listen in to hear me discuss a recent prostate cancer screening event I participated in where over one hundred people got screened.    What You'll Learn: Dr. Rosalyn describes the importance of free cancer screenings. (1:30) Volunteers are essential to a successful free cancer screening event. (4:00) Some prostate cancer survivors volunteered. (5:45) The pandemic caused people to delay their cancer screenings.  (7:15)   "Free cancer screenings are so beneficial for people who don't have access to medical care." - Dr. Rosalyn Morrell "Cancer prevention is extremely important and cancer screenings are a big part of that." - Dr. Rosalyn   Resources: Rosalyn Morrell, MD: Website

Navigating guidelines, parsing through the PSA, Survivorship, & More! Become a pro when addressing prostate cancer! We tackle the nuances surrounding screening for this all-to-common cancer and discuss important considerations in survivorship with our guest Dr. Petar Bajic (Twitter: @PBajicMD, Instagram: @the.sexdoc) of Cleveland Clinic! You're IN for a good time listening to this episode! Claim free CME for this episode at curbsiders.vcuhealth.org! Episodes | Subscribe | Spotify | Swag! | Top Picks | Mailing List | askcurbsiders@gmail.com | Free CME! Show Segments ●      Intro, disclaimer, guest bio ●      Guest one-liner ●      Case from Kashlak ●      Epidemiology of Prostate Cancer ●      Screening Basics ●      What is the PSA? ●      Next Steps After Elevated PSA ●      Thresholds and techniques for biopsy ●      Free PSA, Other testing modalities, Prostate MRI ●      Active Surveillance Nuts and Bolts ●      Survivorship ●      Take home points, Outro Credits ●      Producer,Writer, Show Notes,  Infographic, Cover Art: Beth Garbitelli MD ●      Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP, Beth Garbitelli MD ●      Reviewer: Sai S Achi, MD MBA ●      Showrunner: Matthew Watto MD, FACP; Paul Williams MD, FACP ●      Technical Production: PodPaste ●      Guest: Dr. Petar Bajic MD Sponsor: Better Help  Learn more and save 10% off your first month ast betterhelp.com/curb Sponsor: Birch Living  Birch is giving $400 off all mattresses and 2 free eco-rest pillows at birchliving.com/curb Sponsor: Hello Fresh Go to hellofresh.com/curb18 and use code curb18 for 18 free meals plus free shipping.  Sponsor: Pattern Life Visit patternlife.com/curbsiders to request your free physician disability insurance quote. Full Transcript HERE

Our special 2-part episode series concludes as we go on call with Dr. Fenwa Milhouse, a fellowship-trained, board certified Urologist, to talk about all things Urology. While the last discussion focused on prostate cancer screening information, this episode dives deep into erectile dysfunction. Dr. Milhouse shares a full rundown of potential causes, prevention measures, and even tools that can help erectile dysfunction while explaining other potentially connected health conditions. She even goes in-depth about how she encourages patients to let their guard down in order to truly create a comfortable environment for this taboo topic.    Contact Dr. Randy Hines II: https://www.drrandymd.com IG: @_drrandy FB: @HinesEntertainment   LinkedIn: Dr. Randy Hines II Twitter: @_DrRandy   Contact Dr. Fenwa Milhouse: www.yourfavoriteurologist.com IG: @drmilhouse TikTok: @yourfavoriteurologist

We're talking all things Urology in this special 2-part episode series of "On Call with Dr. Randy." Dr. Fenwa Milhouse, a fellowship-trained, board certified Urologist, joins the show to discuss in depth about prostate cancer and erectile dysfunction. In the first part of the series, Dr. Milhouse takes us through the ins and outs of prostate cancer including risk factors, patient advocacy, signs and symptoms and research efforts. She even discusses her journey to becoming an Urologist while urging the need for more women to join the field. Stay tuned next week to experience Part 2 of this insightful discussion!    Contact Dr. Randy Hines II: https://www.drrandymd.com IG: @_drrandy FB: @HinesEntertainment   LinkedIn: Dr. Randy Hines II Twitter: @_DrRandy   Contact Dr. Fenwa Milhouse: www.yourfavoriteurologist.com - COMING SOON! IG: @drmilhouse TikTok: @yourfavoriteurologist

In this episode, we discuss prostate cancer screening.  Prostate cancer is the most common cancer in men and yet screening for prostate cancer is considered quite controversial. Many sources state that prostate cancer is slow growing and that, as a result, prostate cancer screening is just not warranted. At the same time, prostate cancer takes the lives of about 34,000 American men every year. So what should guys do? Who should get screened? What does that even entail? Are there options as to how to get screened? Are there risks involved? To help us sort through these questions we turn to a true expert, Dr. Ganesh Palapattu is professor and chairman of the Department of Urology at the University of Michigan. Dr. Palapattu completed his undergraduate studies at the University of Texas at Austin and earned his medical degree from the Baylor College of Medicine. He underwent his residency training in urology at UCLA and then completed a fellowship in urologic oncology at Johns Hopkins.  After completing his training Dr. Palapattu held a faculty appointment at the University of Rochester School of Medicine, and then served as the chief of urologic oncology at the Methodist Hospital in Houston, Texas. In 2012, Dr. Palapattu was appointed associate professor and chief of urologic oncology at the University of Michigan, where he later became chair of the urology department. 

September is Prostate Cancer Awareness Month.  Men often ask Dr. Pohlman about when it will be the right time for them to start getting checked for prostate cancer. For this episode, we circle back to Episode 32, where Dr. Matt Cooperberg, from the University of California, San Francisco, spoke about prostate cancer screening. The way that men get screened for prostate cancer continues to evolve. Today, Dr. Cooperberg answers all your burning questions and explains how you can be smarter when it comes to detecting prostate cancer. Stay tuned for more! Dr. Cooperberg earned his MD and MPH degrees at Yale University, and he completed his residency in urology and fellowship in urologic oncology at UCSF. At the end of his training, Dr. Cooperberg joined the faculty at UCSF, where he maintains busy clinical practices at the UCSF Hellen Diller Family Comprehensive Cancer Center and the San Francisco VA Medical Center. He has written or contributed to over 350 research articles. Through his clinical and research efforts, he continues to lead the way for a paradigm shift for smarter prostate cancer screening with rational and risk-stratified prostate cancer screening, as well as appropriate risk-stratified treatment strategies. Stay tuned for more! Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation.  Show highlights: Dr. Cooperberg reviews how commonly prostate cancer occurs. How prostate cancer is detected. How prostate cancer screening has evolved over the years. Dr. Cooperberg explains what smart prostate screening is. When low-risk prostate cancer gets found with smart screening, it does not get treated. The benefits of smart prostate screening. The tests Dr. Cooperberg prefers for finding more information and deciding whether or not to do a biopsy. The age at which Dr. Cooperberg typically recommends men start undergoing prostate cancer screening. How long do men need to keep on getting screened for prostate cancer as they get older? Dr. Cooperberg describes the patients he views as ideal candidates for active surveillance. Dr. Cooperberg discusses his currently preferred active surveillance protocol.   Links:  Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd  Get your free What To Expect Guide (or find the link here, on our podcast website)   Join our Facebook group  Follow Dr. Pohlman on Twitter and Instagram  Go to the Prostate Health Academy to sign up for the wait-list for our bonus video content.  You can access Dr. Pohlman's free mini webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here.